According to the American Academy of Ophthalmology, in 2013, 17 million cases of proliferative diabetic retinopathy were observed globally. Diabetic retinopathy cases exclusively require vitrectomy and therefore held responsible for driving the market for vitreous tamponades. Moreover, the growth of tamponades market is being driven by aging population and onset of diabetes which is occurring at an epidemic rate. Similarly, according to the International Diabetes Federation, around 300 million people were affected with diabetes globally in 2010 and this figure is likely to reach 438 million by 2030. Thus, rising diabetic cases that could lead to impaired vision and blindness if left untreated would rise the demand for tamponades.
Get the Futuristic Market Trends of Vitreous Tamponades at: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4233
Geographically, the global vitreous tamponade market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America was observed to be the largest regional market globally in terms of revenue in 2013. In the U.S. retinal detachment is one of the major causes of morbidity with an incidence between 10.1 and 17.9 per 100,000 populations. Furthermore, according to the data published by Medicare in Ocular Surgery News, the number of vitrectomy surgeries performed in the U.S. increased by around 80% in 2012 as compared to 1997. Hence, increased incidences of retinal detachment and augmented growth in number of vitrectomy surgeries were the major reasons held responsible for the dominant position of this region. Owing to on label usage of gaseous tamponades, physician preference and ease of use, gaseous tamponades accounted for the largest share of the market in North America. Silicone oils held less than 30% of the market share in 2013 due to high cost and requirement of repeated surgical interventions
Asia Pacific market on the other hand is anticipated to increase their market share and witness promising growth in the near future. Rising geriatric population which are prone to retinal disorders and rapidly evolving medical tourism industry in countries (such as India, Thailand, Singapore and others) are few key reasons that are anticipated to propel the growth of this market. Likewise, increasing incidence rate of type 1 & type 2 diabetes, expanding population base and rising healthcare awareness are other reasons that would indirectly increase the demand of tamponades in this region.
The RoW region is expected to follow the Asia Pacific region in terms of growth rate, making it the second fastest growing market for vitreous tamponades during the forecast period. This is attributed to the growing awareness of vitreoretinal disorders in the African and Latin American region along with increased WHO initiatives such as the vision 2020 that have helped in the timely diagnosis of ophthalmic disorders.
The market for vitreous tampoandes is highly fragmented and each region of the market is dominated by a select number of players. For instance, the vitreous tampoandes industry in North America is dominated by Alcon and Valeant Pharmaceuticals which captures more than 78% of the market share. Furthermore, the Europe and Asian market is fragmented and is dominated by regional players. In these regions, giants such as Alcon and Valeant Pharmaceuticals does not account for a significant share in the vitreous tamponades market. The vitreous tamponades market, therefore, is characterized by the presence Dutch Ophthalmic Research Center B.V., Fluoron GmbH, Croma Pharma AG, and AL.CHI.MI.A Srl, Aurolab and others .
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453